Ascendis Pharma A (ASND) Notes Payables (2021 - 2026)

Ascendis Pharma A has reported Notes Payables for 6 years, with the latest figure at $524.7 million in Q1 2026.

• Quarterly Notes Payables rose 10.96% year-over-year to $524.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $524.7 million (up 10.96% YoY) and the FY2025 annual result came in at $499.8 million, up 2.08% from the prior year.
• Notes Payables advanced to $524.7 million in Q1 2026 per ASND's latest filing, from $499.8 million in the prior quarter.
• Over five years, Notes Payables peaked at $598.2 million in Q3 2023 and troughed at $395.4 million in Q4 2022.
• A 5-year average of $494.6 million and a median of $498.3 million in 2025 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2022 and 2024: Notes Payables soared 252.82% in 2022, then fell 22.51% in 2024.
• Over 5 years, Notes Payables stood at $395.4 million in 2022, then grew by 10.78% to $438.0 million in 2023, then increased by 11.79% to $489.6 million in 2024, then climbed by 2.08% to $499.8 million in 2025, then rose by 4.98% to $524.7 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $524.7 million, $499.8 million, and $498.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.